VKH
AVTX icon

Virtu KCG Holdings’s Avalo Therapeutics AVTX Stock Holding History

Virtu KCG Holdings’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$23K Sell
14
-1
-7% -$1.63K ﹤0.01% 2711
2017
Q1 		$30K Sell
15
-9
-38% -$21.5K ﹤0.01% 2922
2016
Q4 		$61K Buy
+24
New +$219K ﹤0.01% 3041

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return

Virtu KCG Holdings's AVTX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Avalo Therapeutics (AVTX) stake by 6.7% in Q2 2017, selling an estimated $1.63K and leaving 14 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

Virtu KCG Holdings first reported a position in AVTX in Q4 2016 and has held it in 3 quarters since. The position peaked at $61K in Q4 2016. 9 funds tracked by Wall St. Rank hold AVTX as of Q2 2017.

  • Virtu KCG Holdings held 14 shares of Avalo Therapeutics worth $23K as of Q2 2017.
  • Virtu KCG Holdings sold 1 Avalo Therapeutics share in Q2 2017, an estimated $1.63K.
  • Avalo Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2711 holding.
  • Virtu KCG Holdings first reported a position in Avalo Therapeutics in Q4 2016 and has held it in 3 quarters since.
  • Virtu KCG Holdings's Avalo Therapeutics position peaked at $61K in Q4 2016.
  • 9 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.